FDA Division of OTC Drug Evaluation
Executive Summary
William Pierson, MD, University of Washington, recently became a consultant to the division's Eye, Ear, Nose, Throat and Oral Cavity Drug Monograph Branch. He is working with FDA in evaluating his suggestion to the Pulmonary-Allergy Drugs Advisory Committee that the warning statement in prescription and OTC antihistamine labeling that contraindicates use in asthma patients be removed. At its June 12 meeting, the committee agreed with Pierson's proposal.